APA (7th ed.) Citation

Cheng, W., Shen, C., Liang, Y., Chiao, M., Yang, Y., Hsieh, W., . . . Chen, J. (2023). Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme. BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-11400-5

Chicago Style (17th ed.) Citation

Cheng, Wen-Yu, Chiung-Chyi Shen, Yea-Jiuen Liang, Ming-Tsang Chiao, Yi-Chin Yang, Wan-Yu Hsieh, Cheng-Hui Lin, and Jun-Peng Chen. "Polymorphism at Codon 31 of CDKN1A (p21) as a Predictive Factor for Bevacizumab Therapy in Glioblastoma Multiforme." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-11400-5.

MLA (9th ed.) Citation

Cheng, Wen-Yu, et al. "Polymorphism at Codon 31 of CDKN1A (p21) as a Predictive Factor for Bevacizumab Therapy in Glioblastoma Multiforme." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-11400-5.